Published in HIV Med on October 14, 2010
Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther (2012) 1.71
Clinical implications of HIV-1 minority variants. Clin Infect Dis (2013) 1.09
Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J Virol (2012) 0.86
Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission? HIV Med (2011) 0.76
Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance. J Acquir Immune Defic Syndr (2016) 0.75
Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014. J Int AIDS Soc (2017) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet (2011) 10.73
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
floricaula: a homeotic gene required for flower development in antirrhinum majus. Cell (1990) 6.52
Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana. Nature (1998) 5.91
Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol (2001) 5.05
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ (2005) 4.91
FCA, a gene controlling flowering time in Arabidopsis, encodes a protein containing RNA-binding domains. Cell (1997) 4.79
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Effects of a decision support system on the diagnostic accuracy of users: a preliminary report. J Am Med Inform Assoc (1997) 4.61
Multiple independent defective suppressor-mutator transposon insertions in Arabidopsis: a tool for functional genomics. Plant Cell (1999) 4.57
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: estimates of radiation-related cancer risks. Radiat Res (2007) 4.41
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ (2000) 4.31
Undescribed toxin in pseudomembranous colitis. Br Med J (1977) 4.31
Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health (2000) 4.25
Genetic definition and sequence analysis of Arabidopsis centromeres. Science (1999) 4.20
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 3.97
Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet (1987) 3.91
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem (1985) 3.51
HIV surveillance by testing saliva. AIDS (1988) 3.43
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem (1996) 3.00
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett (1992) 2.88
Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet (1981) 2.86
Detection of measles, mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay. J Med Virol (1993) 2.85
Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect (2004) 2.76
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Role of viruses in febrile convulsions. Arch Dis Child (1979) 2.72
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol Rev (2001) 2.69
Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill (2008) 2.66
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
A glutamate decarboxylase system protects Listeria monocytogenes in gastric fluid. Mol Microbiol (2001) 2.63
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Sequence and analysis of the 60 kb conjugative, bacteriocin-producing plasmid pMRC01 from Lactococcus lactis DPC3147. Mol Microbiol (1998) 2.61
Conservation of microstructure between a sequenced region of the genome of rice and multiple segments of the genome of Arabidopsis thaliana. Genome Res (2001) 2.56
Molecular characterization and regulation of the rhizosphere-expressed genes rhiABCR that can influence nodulation by Rhizobium leguminosarum biovar viciae. J Bacteriol (1992) 2.55
Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996. Commun Dis Public Health (1999) 2.55
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ (2001) 2.53
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A (1991) 2.53
Risk behaviour, anti-HIV and anti-hepatitis B core prevalence in clinic and non-clinic samples of gay men in England, 1991-1992. AIDS (1993) 2.50
The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem (1996) 2.45
An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol (1996) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Airborne spread of measles in a suburban elementary school. Am J Epidemiol (1978) 2.37
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol (2000) 2.33
Evidence that latent collagenases are enzyme-inhibitor complexes. Biochem J (1977) 2.32
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci (1997) 2.28
Measles virus antibody in aqueous humour of patients with uveitis associated with multiple sclerosis. Lancet (1992) 2.26
Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Adaptive acid tolerance response in Listeria monocytogenes: isolation of an acid-tolerant mutant which demonstrates increased virulence. Appl Environ Microbiol (1996) 2.24
Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun (2011) 2.24
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components. Biochem J (1983) 2.17
Preliminary report: accurate assays for anti-HIV in urine. Lancet (1990) 2.17
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Long-term persistence of Coxiella burnetii after acute primary Q fever. QJM (2005) 2.15
Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen (2000) 2.15
Prevalence of HIV infection in patients attending an inner city accident and emergency department. BMJ (1994) 2.15
Identification and disruption of lisRK, a genetic locus encoding a two-component signal transduction system involved in stress tolerance and virulence in Listeria monocytogenes. J Bacteriol (1999) 2.14
Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol (1997) 2.13
Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem (2000) 2.12
Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet (1999) 2.12
Purification of rabbit bone inhibitor of collagenase. Biochem J (1981) 2.12
Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine. J Med Virol (1993) 2.11
Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Relationship between x-ray exposure and malignant transformation in C3H 10T1/2 cells. Proc Natl Acad Sci U S A (1980) 2.08
Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by reverse transcription and polymerase chain reaction amplification. J Clin Microbiol (1992) 2.08
Effect sizes and p values: what should be reported and what should be replicated? Psychophysiology (1996) 2.07
Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample of homosexual men. Sex Transm Infect (2004) 2.06
Eu oxidation state in fluorozirconate-based glass ceramics. J Appl Phys (2009) 2.06
Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab (2012) 2.06
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain. Oncol Nurs Forum (1998) 2.03
Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. Haemophilia (2010) 2.03
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01